3UE8

Kynurenine Aminotransferase II Inhibitors


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.22 Å
  • R-Value Free: 0.275 
  • R-Value Work: 0.200 
  • R-Value Observed: 0.204 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia.

Dounay, A.B.Anderson, M.Bechle, B.M.Campbell, B.M.Claffey, M.M.Evdokimov, A.Evrard, E.Fonseca, K.R.Gan, X.Ghosh, S.Hayward, M.M.Horner, W.Kim, J.Y.McAllister, L.A.Pandit, J.Paradis, V.Parikh, V.D.Reese, M.R.Rong, S.Salafia, M.A.Schuyten, K.Strick, C.A.Tuttle, J.B.Valentine, J.Wang, H.Zawadzke, L.E.Verhoest, P.R.

(2012) ACS Med Chem Lett 3: 187-192

  • DOI: 10.1021/ml200204m
  • Primary Citation of Related Structures:  
    3UE8

  • PubMed Abstract: 
  • Kynurenine aminotransferase (KAT) II has been identified as a potential new target for the treatment of cognitive impairment associated with schizophrenia and other psychiatric disorders. Following a high-throughput screen, cyclic hydroxamic acid PF-04859989 was identified as a potent and selective inhibitor of human and rat KAT II ...

    Kynurenine aminotransferase (KAT) II has been identified as a potential new target for the treatment of cognitive impairment associated with schizophrenia and other psychiatric disorders. Following a high-throughput screen, cyclic hydroxamic acid PF-04859989 was identified as a potent and selective inhibitor of human and rat KAT II. An X-ray crystal structure and (13)C NMR studies of PF-04859989 bound to KAT II have demonstrated that this compound forms a covalent adduct with the enzyme cofactor, pyridoxal phosphate (PLP), in the active site. In vivo pharmacokinetic and efficacy studies in rat show that PF-04859989 is a brain-penetrant, irreversible inhibitor and is capable of reducing brain kynurenic acid by 50% at a dose of 10 mg/kg (sc). Preliminary structure-activity relationship investigations have been completed and have identified the positions on this scaffold best suited to modification for further optimization of this novel series of KAT II inhibitors.


    Organizational Affiliation

    Pfizer Worldwide Research and Development , Neuroscience Chemistry, Eastern Point Road, Groton, Connecticut 06340, United States.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Kynurenine/alpha-aminoadipate aminotransferase, mitochondrialA, B439Homo sapiensMutation(s): 0 
Gene Names: AADATKAT2
EC: 2.6.1.39 (PDB Primary Data), 2.6.1.7 (PDB Primary Data)
Find proteins for Q8N5Z0 (Homo sapiens)
Explore Q8N5Z0 
Go to UniProtKB:  Q8N5Z0
NIH Common Fund Data Resources
PHAROS:  Q8N5Z0
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
09M
Query on 09M

Download Ideal Coordinates CCD File 
C [auth A], E [auth B](5-hydroxy-4-{[(1-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl)amino]methyl}-6-methylpyridin-3-yl)methyl dihydrogen phosphate
C17 H18 N3 O7 P
ZKPXUQQBRMXHLJ-UHFFFAOYSA-N
 Ligand Interaction
CL
Query on CL

Download Ideal Coordinates CCD File 
D [auth A], F [auth B]CHLORIDE ION
Cl
VEXZGXHMUGYJMC-UHFFFAOYSA-M
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.22 Å
  • R-Value Free: 0.275 
  • R-Value Work: 0.200 
  • R-Value Observed: 0.204 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 63.616α = 90
b = 116.597β = 90
c = 129.267γ = 90
Software Package:
Software NamePurpose
StructureStudiodata collection
AMoREphasing
BUSTERrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2012-02-01
    Type: Initial release
  • Version 1.1: 2018-04-18
    Changes: Data collection, Database references